CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia

Trial Profile

CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 May 2018

At a glance

  • Drugs Chimeric-antigen-receptor-T-cell-therapeutics-Shanghai-Unicar-Therapy-Bio-medicine-Technology (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Sponsors Shanghai Unicar-Therapy Bio-medicine Technology
  • Most Recent Events

    • 21 May 2018 Planned End Date changed from 18 Feb 2019 to 18 Feb 2020.
    • 21 May 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
    • 08 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top